- Home
- IMAB vs CTOR Comparison
IMAB vs CTOR Comparison
Compare IMAB & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- CTOR
- Stock Information
- Founded
- IMAB 2014
- CTOR 2021
- Country
- IMAB United States
- CTOR United States
- Employees
- IMAB N/A
- CTOR N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- IMAB Health Care
- CTOR
- Exchange
- IMAB Nasdaq
- CTOR NYSE
- Market Cap
- IMAB 79.9M
- CTOR 89.9M
- IPO Year
- IMAB 2020
- CTOR N/A
- Fundamental
- Price
- IMAB $0.97
- CTOR $1.17
- Analyst Decision
- IMAB Strong Buy
- CTOR Strong Buy
- Analyst Count
- IMAB 3
- CTOR 2
- Target Price
- IMAB $8.00
- CTOR $4.50
- AVG Volume (30 Days)
- IMAB 270.1K
- CTOR 61.5K
- Earning Date
- IMAB 03-13-2025
- CTOR 02-14-2025
- Dividend Yield
- IMAB N/A
- CTOR N/A
- EPS Growth
- IMAB N/A
- CTOR N/A
- EPS
- IMAB N/A
- CTOR N/A
- Revenue
- IMAB $569,464.00
- CTOR N/A
- Revenue This Year
- IMAB N/A
- CTOR N/A
- Revenue Next Year
- IMAB N/A
- CTOR N/A
- P/E Ratio
- IMAB N/A
- CTOR N/A
- Revenue Growth
- IMAB N/A
- CTOR N/A
- 52 Week Low
- IMAB $0.84
- CTOR $0.85
- 52 Week High
- IMAB $2.00
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- IMAB 46.51
- CTOR N/A
- Support Level
- IMAB $0.96
- CTOR N/A
- Resistance Level
- IMAB $1.04
- CTOR N/A
- Average True Range (ATR)
- IMAB 0.05
- CTOR 0.00
- MACD
- IMAB -0.00
- CTOR 0.00
- Stochastic Oscillator
- IMAB 36.36
- CTOR 0.00
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.